These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8165617)

  • 1. Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma.
    Zammit A; Pepper DS; Dawes J
    Thromb Haemost; 1993 Dec; 70(6):951-8. PubMed ID: 8165617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins.
    Young E; Cosmi B; Weitz J; Hirsh J
    Thromb Haemost; 1993 Oct; 70(4):625-30. PubMed ID: 8115988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization of the anticoagulant effects of glycosaminoglycans by serum amyloid P component: comparison with other plasma and platelet proteins.
    Williams EC; Huppert BJ; Asakura S
    J Lab Clin Med; 1992 Jul; 120(1):159-67. PubMed ID: 1377216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mode of action of enoxaparin in plasma.
    Béguin S; Hemker HC
    Acta Chir Scand Suppl; 1990; 556():51-6. PubMed ID: 1963017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of heparin with histidine-rich glycoprotein and with antithrombin III.
    Lijnen HR; van Hoef B; Collen D
    Thromb Haemost; 1983 Aug; 50(2):560-2. PubMed ID: 6415849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of heparins in the vascular environment.
    Dawes J
    Haemostasis; 1993 Mar; 23 Suppl 1():212-9. PubMed ID: 8388354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rational approach to heparins.
    Hemker HC; Béguin S
    Nouv Rev Fr Hematol (1978); 1992; 34(1):5-9. PubMed ID: 1326098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.
    Zammit A; Dawes J
    Thromb Haemost; 1994 Jun; 71(6):759-67. PubMed ID: 7526481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interaction of heparin with plasma proteins. Demonstration of different binding sites for antithrombin III complexes and antithrombin III.
    McKay EJ; Laurell CB
    J Lab Clin Med; 1980 Jan; 95(1):69-80. PubMed ID: 7350242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term persistence of biological activity following administration of Enoxaparin sodium (clexane) is due to sequestration of antithrombin-binding low molecular weight fragments--comparison with unfractionated heparin.
    Brieger D; Dawes J
    Thromb Haemost; 1996 May; 75(5):740-6. PubMed ID: 8725716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histidine-rich glycoprotein modulates the anticoagulant activity of heparin in human plasma.
    Lijnen HR; Van Hoef B; Collen D
    Thromb Haemost; 1984 Apr; 51(2):266-8. PubMed ID: 6740558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of heparin fractions to von Willebrand factor: effect of molecular weight and affinity for antithrombin III.
    Baruch D; Ajzenberg N; Denis C; Legendre P; Lormeau JC; Meyer D
    Thromb Haemost; 1994 Jan; 71(1):141-6. PubMed ID: 8165633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.
    Martinez-Sales V; Vila V; Réganon E; Oms JG; Aznar J
    Haematologica; 2003 Jun; 88(6):694-9. PubMed ID: 12801846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
    Vila V; Martínez-Sales V; Réganon E; Peris E; Perez F; Ruano M; Aznar J
    Haematologica; 2001 Jul; 86(7):729-34. PubMed ID: 11454528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
    Diquélou A; Dupouy D; Cariou R; Sakariassen KS; Boneu B; Cadroy Y
    Thromb Haemost; 1995 Nov; 74(5):1286-92. PubMed ID: 8607111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins.
    Jeske W; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 3():27-33. PubMed ID: 10549713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of intravenously administered radiolabelled antithrombin III and heparin in humans.
    de Swart CA; Nijmeyer B; Andersson LO; Holmer E; Sixma JJ; Bouma BN
    Thromb Haemost; 1984 Aug; 52(1):66-70. PubMed ID: 6495266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.